Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single ascending-dose injectable favipiravir study in healthy male volunteers
jRCT2071210042Phase 1Active, not recruiting
- Sponsor
- FUJIFILM Toyama Chemical
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in severe fever with thrombocytopenia syndrome (SFTS) comparing Injectable favipiravir with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jul 2021; status: active, not recruiting.
02
Drugs
favipiravir
03
Conditions
severe fever with thrombocytopenia syndrome (SFTS)
Beyond the preview
Go deeper on jRCT2071210042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210042.